Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100cm2 on the forearm(s) of patients with actinic keratosis

Journal of Clinical and Aesthetic Dermatology

Volumn 7, Issue 12, 2014, Pages 19-29

  Anderson, Lawrence ^a   Jarratt, Michael ^b   Schmieder, George ^c   Shumack, Stephen ^d   Katsamas, Janelle ^e   Welburn, Peter ^e  

^a Dermatology Associates of Tyler   (United States)

^b DermResearch Inc   (United States)

^c Park Avenue Dermatology   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Clive Berghofer Cancer Research Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INGENOL MEBUTATE;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CRACKLE; CUTANEOUS PARAMETERS; DESQUAMATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ENTEROPATHY; ERYTHEMA; FEMALE; FOLLOW UP; FOREARM; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOPIGMENTATION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN COMPOSITE LOCAL SKIN RESPONSE SCORE; MULTICENTER STUDY; OPEN STUDY; PANCREATITIS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PUSTULE; SCAR FORMATION; SKIN EROSION; SKIN ULCER; SWELLING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VESICULAR RASH; XEROSTOMIA;

EID: 84919467032     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39-44.
2. Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology. 2008;216:194-199.
3. de Berker D, Mcgregor JM, hughes BR. guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-230.
4. Marks R, Rennie g, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797.
5. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37:677-681.
6. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer. 1997;79:920-923.
7. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23-24.
8. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189-196.
9. Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17:67-76.
10. Goldberg LH, Kaplan B, Vergilis-Kalner I, Landau J. Liquid nitrogen: temperature control in the treatment of actinic keratosis. Dermatol Surg. 2010;36:1956-1961.
11. Krawtchenko N, Roewert-huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34-40.
12. Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111-122.
13. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010-1019.
14. Lebwohl M, Shumack S, gold LS, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666-670.
15. Allergan Inc. Fluoroplex (fluorouracil) 1% topical cream. Prescribing information. Last update 2004. Available at: http://www.allergan.com/assets/pdf/fluoroplex-pi.pdf. Accessed April 26, 2013.
16. Almirall Ltd. Solaraze. Summary of product characteristics. Last update 2012. Available at: http://www.medicines.org. uk/emc/medicine/21229/SPC. Accessed April 30, 2014.
17. electronic Medicines Consortium (eMC). Solaraze SmPC. Last update 2012. Available at: http://www.medicines.org. uk/emc/medicine/21229/SPC. Accessed April 10, 2014.
18. Food and Drug Administration (FDA). Zyclara (imiquimod) cream, 3.75%. Prescribing information, graceway Pharmaceuticals. Last update 2011. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/201153s000,0224 83s001lbl.pdf. Accessed April 30, 2014.
19. 3M health Care Limited. Aldara (Imiquimod): highlights of prescribing information. Last update 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/020723s020lbl.pdf. Accessed June 4, 2014.
20. graceway Pharmaceuticals. Aldara (imiquimod) cream, 5%. Prescribing information. Last update 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020723s022lbl.pdf. Accessed April 30, 2014.
21. Pharmaderm. Solaraze gel. Prescribing information. Last update 2011. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021005s013lbl.pdf. Accessed April 10, 2014.
22. Sanofi. Carac cream, 0.5% (fluorouracil cream). Prescribing information. Last update 2009. Available at: http://products. sanofi.us/carac/carac.pdf. Accessed July 1, 2014.
23. International Conference on harmonisation of Technical Requirements for Registration of Pharmaceuticals for human Use (ICh). guideline for good Clinical Practice. Last update 1996. Available at: http://www.ich.org/file admin/Public-Web- Site/ICh-Products/guidelines/efficacy/e6-R1/Step4/e6-R1- -guideline.pdf. Accessed April 30, 2014.
24. World Medical Association. World Medical Association Declaration of helsinki. ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79:373-374.
25. Rosen R, Marmur e, Anderson L, et al. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy. Dermatol Ther (Heidelb). 2014 Jul 30. [epub ahead of print].
26. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res. 2004;296:6-11.
27. Cantisani C, Lazic T, Richetta Ag, et al. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6:65-69.
28. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157(Suppl 2):41-46.
29. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J. 2005;118:U1682.
30. Heikkinen AK, Susitaival P. Severe systemic reaction to topical imiquimod. Acta Derm Venereol. 2011;91:594-595.
31. Kulp J, Levy S, Fein MC, et al. Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. Arch Dermatol Res. 2010;302:539-544.
32. Abramowitz M (ed). Systemic reactions to imiquimod (Aldara). Med Lett Drugs Ther. 2004;46:92.
33. Cohn BA. From sunlight to actinic keratosis to squamous cell carcinoma. J Am Acad Dermatol. 2000;42:143-144.
34. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013;8:35-41.
35. Dosik JS, Damstra M, Udell C, Welburn P. evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7:35-42.
36. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934-943.